drugset / Trial / NCT02040532

Gabapentin for Insomnia Symptoms and Nighttime Vasomotor Symptoms (VMS) in Peri- and Postmenopausal Women

NCT02040532

NaSingle-groupOpen-labelTreatment

Summary

The broad goal of this study is to obtain pilot data to determine the tolerability and preliminary efficacy of the non-hormonal agent gabapentin for insomnia symptoms and nighttime vasomotor Symptoms (VMS) when open-label gabapentin is administered at low dose and only at night in peri- and postmenopausal women. We hypothesize that the majority of participants will be able to increase and tolerate treatment, and insomnia symptoms and the frequency of nighttime VMS will improve on low-dose gabapentin dosed at bedtime.

Timeline

Start
2014-01
Primary completion
2015-08
Completion
2015-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Gabapentin Small molecule 600 mg

Indications